Economic Burden Analysis of Parkinson’s Disease Patients in China
Background and Objective. Parkinson’s Disease (PD) is a progressive neurodegenerative disorder, which is prevalent in people over 65 years old. PD reduces patients’ quality of life and exerts a heavy economic burden on patients and their families. The purpose of this research is to identify the cost...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2017/8762939 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551581121249280 |
|---|---|
| author | Jun-Xiu Yang Lei Chen |
| author_facet | Jun-Xiu Yang Lei Chen |
| author_sort | Jun-Xiu Yang |
| collection | DOAJ |
| description | Background and Objective. Parkinson’s Disease (PD) is a progressive neurodegenerative disorder, which is prevalent in people over 65 years old. PD reduces patients’ quality of life and exerts a heavy economic burden on patients and their families. The purpose of this research is to identify the costs of PD and to evaluate the economic distribution of medical care for PD patients in China. Methods. A professional survey was administered to 116 patients with PD. Records of medical cost were reviewed. Direct and indirect costs were analyzed. The main cost-driving factors of PD were identified using multivariate regression analysis. Results. The average annual cost per PD patient in China is $3,225.94, with direct and indirect costs accounting for $2,503.46 and $722.48, respectively. Direct costs consist of $556.27 for surgery, $44.67 for appointment fees, $605.67 for prescription medication, $460.29 for hospitalization, $71.03 for auxiliary examination, $35.64 for transportation, $10.39 for special equipment, and $719.50 for formal care. The total cost is closely related to surgical treatment, dopamine agonist, and levodopa costs. Conclusion. The cost of PD patients in China is considerable and exceeds average economic capacity, especially antiparkinson medication and caring costs. This study may provide a reference for PD healthcare optimization in the future. |
| format | Article |
| id | doaj-art-0b2b5cd83a6847e2aac51f1f4cfda2d7 |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-0b2b5cd83a6847e2aac51f1f4cfda2d72025-02-03T06:00:58ZengWileyParkinson's Disease2090-80832042-00802017-01-01201710.1155/2017/87629398762939Economic Burden Analysis of Parkinson’s Disease Patients in ChinaJun-Xiu Yang0Lei Chen1Department of Neurology, Tianjin Union Medical Center, Tianjin 300121, ChinaDepartment of Neurology, Tianjin Union Medical Center, Tianjin 300121, ChinaBackground and Objective. Parkinson’s Disease (PD) is a progressive neurodegenerative disorder, which is prevalent in people over 65 years old. PD reduces patients’ quality of life and exerts a heavy economic burden on patients and their families. The purpose of this research is to identify the costs of PD and to evaluate the economic distribution of medical care for PD patients in China. Methods. A professional survey was administered to 116 patients with PD. Records of medical cost were reviewed. Direct and indirect costs were analyzed. The main cost-driving factors of PD were identified using multivariate regression analysis. Results. The average annual cost per PD patient in China is $3,225.94, with direct and indirect costs accounting for $2,503.46 and $722.48, respectively. Direct costs consist of $556.27 for surgery, $44.67 for appointment fees, $605.67 for prescription medication, $460.29 for hospitalization, $71.03 for auxiliary examination, $35.64 for transportation, $10.39 for special equipment, and $719.50 for formal care. The total cost is closely related to surgical treatment, dopamine agonist, and levodopa costs. Conclusion. The cost of PD patients in China is considerable and exceeds average economic capacity, especially antiparkinson medication and caring costs. This study may provide a reference for PD healthcare optimization in the future.http://dx.doi.org/10.1155/2017/8762939 |
| spellingShingle | Jun-Xiu Yang Lei Chen Economic Burden Analysis of Parkinson’s Disease Patients in China Parkinson's Disease |
| title | Economic Burden Analysis of Parkinson’s Disease Patients in China |
| title_full | Economic Burden Analysis of Parkinson’s Disease Patients in China |
| title_fullStr | Economic Burden Analysis of Parkinson’s Disease Patients in China |
| title_full_unstemmed | Economic Burden Analysis of Parkinson’s Disease Patients in China |
| title_short | Economic Burden Analysis of Parkinson’s Disease Patients in China |
| title_sort | economic burden analysis of parkinson s disease patients in china |
| url | http://dx.doi.org/10.1155/2017/8762939 |
| work_keys_str_mv | AT junxiuyang economicburdenanalysisofparkinsonsdiseasepatientsinchina AT leichen economicburdenanalysisofparkinsonsdiseasepatientsinchina |